Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b | Zendy

CH Polman | Zendy; Ludwig Kappos | Zendy; Mark S. Freedman | Zendy; Gilles Edan | Zendy; H-P Hartung | Zendy; David H. Miller | Zendy; Xavier Montalbán | Zendy; Frederik Barkhof | Zendy; Krzysztof Selmaj | Zendy; Bernard M.J. Uitdehaag | Zendy; S. Dahms | Zendy; Lars Bauer | Zendy; Christoph Pohl | Zendy; Rupert Sandbrink | Zendy

AI Assistant Blog Pricing

Open Access

Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b

Author(s) -

CH Polman,

Ludwig Kappos,

Mark S. Freedman,

Gilles Edan,

H-P Hartung,

David H. Miller,

Xavier Montalbán,

Frederik Barkhof,

Krzysztof Selmaj,

Bernard M.J. Uitdehaag,

S. Dahms,

Lars Bauer,

Christoph Pohl,

Rupert Sandbrink

Publication year - 2007

Publication title -

journal of neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.541

H-Index - 136

eISSN - 1432-1459

pISSN - 0340-5354

DOI - 10.1007/s00415-007-0733-2

Subject(s) - medicine , placebo , multiple sclerosis , neurology , clinically isolated syndrome , neuroradiology , disease , population , lesion , magnetic resonance imaging , gastroenterology , surgery , radiology , pathology , immunology , alternative medicine , environmental health , psychiatry

The BENEFIT study examined interferon beta (IFNB)-1b treatment in patients with clinically isolated syndrome (CIS) and > or = 2 clinically silent brain MRI lesions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog